Logo image of LPCN

LIPOCINE INC (LPCN) Stock Fundamental Analysis

NASDAQ:LPCN - Nasdaq - US53630X2036 - Common Stock - Currency: USD

3.2103  -0.05 (-1.52%)

Fundamental Rating

4

Overall LPCN gets a fundamental rating of 4 out of 10. We evaluated LPCN against 193 industry peers in the Pharmaceuticals industry. While LPCN has a great health rating, there are worries on its profitability. LPCN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LPCN was profitable.
LPCN had a negative operating cash flow in the past year.
LPCN had negative earnings in 4 of the past 5 years.
LPCN had a negative operating cash flow in each of the past 5 years.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M -20M

1.2 Ratios

LPCN has a Return On Assets of -26.20%. This is comparable to the rest of the industry: LPCN outperforms 56.99% of its industry peers.
LPCN's Return On Equity of -27.97% is fine compared to the rest of the industry. LPCN outperforms 64.77% of its industry peers.
Industry RankSector Rank
ROA -26.2%
ROE -27.97%
ROIC N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

LPCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LPCN has been increased compared to 1 year ago.
LPCN has more shares outstanding than it did 5 years ago.
LPCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -5.45, we must say that LPCN is in the distress zone and has some risk of bankruptcy.
LPCN's Altman-Z score of -5.45 is on the low side compared to the rest of the industry. LPCN is outperformed by 62.69% of its industry peers.
LPCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.45
ROIC/WACCN/A
WACC9.9%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 15.64 indicates that LPCN has no problem at all paying its short term obligations.
LPCN has a better Current ratio (15.64) than 88.08% of its industry peers.
LPCN has a Quick Ratio of 15.64. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
LPCN has a better Quick ratio (15.64) than 88.08% of its industry peers.
Industry RankSector Rank
Current Ratio 15.64
Quick Ratio 15.64
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 130.99% over the past year.
The Earnings Per Share has been growing by 213.46% on average over the past years. This is a very strong growth
Looking at the last year, LPCN shows a very negative growth in Revenue. The Revenue has decreased by -22.03% in the last year.
LPCN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 133.89% yearly.
EPS 1Y (TTM)130.99%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%-153.03%
Revenue 1Y (TTM)-22.03%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%-98.78%

3.2 Future

The Earnings Per Share is expected to decrease by -39.74% on average over the next years. This is quite bad
Based on estimates for the next years, LPCN will show a very strong growth in Revenue. The Revenue will grow by 37.92% on average per year.
EPS Next Y-217.56%
EPS Next 2Y-74.26%
EPS Next 3Y-39.74%
EPS Next 5YN/A
Revenue Next Year-92.26%
Revenue Next 2Y-76.71%
Revenue Next 3Y-13.85%
Revenue Next 5Y37.92%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 6.06 indicates a rather cheap valuation of LPCN.
Based on the Price/Earnings ratio, LPCN is valued cheaply inside the industry as 95.85% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.41, LPCN is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for LPCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 6.06
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

LPCN's earnings are expected to decrease with -39.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-74.26%
EPS Next 3Y-39.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LPCN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPOCINE INC

NASDAQ:LPCN (7/14/2025, 2:14:56 PM)

3.2103

-0.05 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners9.73%
Inst Owner Change0%
Ins Owners2.95%
Ins Owner Change0%
Market Cap17.18M
Analysts82.5
Price Target7.52 (134.25%)
Short Float %2.33%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)278.92%
Min EPS beat(2)1.96%
Max EPS beat(2)555.88%
EPS beat(4)4
Avg EPS beat(4)150.83%
Min EPS beat(4)1.96%
Max EPS beat(4)555.88%
EPS beat(8)6
Avg EPS beat(8)87.37%
EPS beat(12)9
Avg EPS beat(12)56.86%
EPS beat(16)12
Avg EPS beat(16)139.3%
Revenue beat(2)1
Avg Revenue beat(2)-21.58%
Min Revenue beat(2)-74.1%
Max Revenue beat(2)30.95%
Revenue beat(4)1
Avg Revenue beat(4)-53.22%
Min Revenue beat(4)-100%
Max Revenue beat(4)30.95%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.26%
EPS NQ rev (1m)-2.56%
EPS NQ rev (3m)2.44%
EPS NY rev (1m)4.05%
EPS NY rev (3m)4.05%
Revenue NQ rev (1m)-36.03%
Revenue NQ rev (3m)-38.11%
Revenue NY rev (1m)-46.91%
Revenue NY rev (3m)-46.91%
Valuation
Industry RankSector Rank
PE 6.06
Fwd PE N/A
P/S 4.67
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)0.53
EY16.51%
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.69
BVpS3.59
TBVpS3.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.2%
ROE -27.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.24%
ROA(5y)-36.72%
ROE(3y)-36.81%
ROE(5y)-49.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.64
Quick Ratio 15.64
Altman-Z -5.45
F-Score3
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)521.74%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.09%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)130.99%
EPS 3Y213.46%
EPS 5YN/A
EPS Q2Q%-153.03%
EPS Next Y-217.56%
EPS Next 2Y-74.26%
EPS Next 3Y-39.74%
EPS Next 5YN/A
Revenue 1Y (TTM)-22.03%
Revenue growth 3Y-11.47%
Revenue growth 5Y133.89%
Sales Q2Q%-98.78%
Revenue Next Year-92.26%
Revenue Next 2Y-76.71%
Revenue Next 3Y-13.85%
Revenue Next 5Y37.92%
EBIT growth 1Y37.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.39%
OCF growth 3YN/A
OCF growth 5YN/A